Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer
暂无分享,去创建一个
P. Kantoff | J. Armenia | Subhiksha Nandakumar | G. Chakraborty | G. Lee | Yuki Yoshikawa | Ying Z. Mazzu | Lina E. Jehane
[1] Henry W. Long,et al. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2) , 2019, Clinical Cancer Research.
[2] V. Constâncio,et al. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients , 2018, Clinical Epigenetics.
[3] Á. Aytés,et al. Epigenetic Regulation in Prostate Cancer Progression , 2018, Current Molecular Biology Reports.
[4] D. Barros-Silva,et al. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis , 2018, Cell Death & Disease.
[5] Chunjiao Song,et al. The potential of microRNAs as human prostate cancer biomarkers: A meta‐analysis of related studies , 2017, Journal of cellular biochemistry.
[6] Menggang Yu,et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy , 2017, JAMA oncology.
[7] N. Socci,et al. miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells. , 2017, Cancer research.
[8] Xiaoqi Liu,et al. MicroRNAs in prostate cancer: Functional role as biomarkers. , 2017, Cancer letters.
[9] A. De Siervi,et al. Implications of microRNA dysregulation in the development of prostate cancer. , 2017, Reproduction.
[10] A. Zoubeidi,et al. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition , 2017, Clinical Cancer Research.
[11] Zendra Zehner,et al. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer , 2017, International journal of molecular sciences.
[12] Gerardo Botti,et al. Micrornas in prostate cancer: an overview , 2017, Oncotarget.
[13] M. Esteller,et al. Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer , 2017, Journal of Hematology & Oncology.
[14] M. Esteller,et al. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors , 2017, Molecular Cancer.
[15] E. Klein,et al. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. , 2016, Cancer research.
[16] C. Walsh,et al. Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer , 2016, The Prostate.
[17] B. Illades-Aguiar,et al. Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection. , 2016, Oncology reports.
[18] E. Lam,et al. Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance , 2016, Current drug targets.
[19] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[20] W. Han,et al. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. , 2014, Cancer letters.
[21] S. Clark,et al. Prostate cancer epigenetic biomarkers: next-generation technologies , 2014, Oncogene.
[22] Mariano J. Alvarez,et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.
[23] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[24] B. Bernstein,et al. Epigenetic Reprogramming in Cancer , 2013, Science.
[25] Hiromu Suzuki,et al. DNA methylation and microRNA dysregulation in cancer , 2012, Molecular oncology.
[26] J. Ji,et al. Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo , 2012, BMC Cancer.
[27] M. Pagano,et al. Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair , 2012, Cell.
[28] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[29] G. Stein,et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2 , 2011, Proceedings of the National Academy of Sciences.
[30] H. Oja,et al. miR‐193b is an epigenetically regulated putative tumor suppressor in prostate cancer , 2010, International journal of cancer.
[31] W. Filipowicz,et al. The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.
[32] G. Kristiansen,et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.
[33] A. D. De Marzo,et al. Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.
[34] Jing Chen,et al. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..
[35] H. Cedar,et al. Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.
[36] Myles Brown,et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. , 2009, Cancer research.
[37] A. Scarpa,et al. Synergistic effect of trichostatin A and 5‐aza‐2′‐deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: A proteomic study , 2009, Proteomics.
[38] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[39] C. Creighton,et al. Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.
[40] R. Rees,et al. DNA demethylation and histone deacetylation inhibition co‐operate to re‐express estrogen receptor beta and induce apoptosis in prostate cancer cell‐lines , 2008, The Prostate.
[41] F. Lyko,et al. Methylation of Human MicroRNA Genes in Normal and Neoplastic Cells , 2007, Cell cycle.
[42] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Carducci,et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Becich,et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Grever,et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells , 2003, Leukemia.
[47] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .
[48] Shadan Ali,et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. , 2012, American journal of translational research.
[49] S. Gore,et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. , 2008, Seminars in hematology.
[50] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[51] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.
[52] Bernhard O. Palsson,et al. Cancer cell lines , 1999 .